University Hospitals Birmingham NHS Foundation Trust

Chapters

StatusDrug nameNICE TAsComments
Status: AmberAmisulpride solution

Consultant initiation only, ESCA

Status: AmberAmisulpride tablets

Consultant initiation only, ESCA

Status: AmberAripiprazole tablets

Supported by ESCA. The GP should be given a rationale for prescribing rather than first line antipsychotics. Approved for use in Tourette's Syndrome.

Status: AmberChlorpromazine injection

ESCA

Status: AmberChlorpromazine syrup

ESCA

Status: AmberChlorpromazine tablets

ESCA

Status: RedClozapine tablets

Only for emergency use in existing patients when inpatient at UHB

Status: RedFlupentixol decanoate injection

Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion).

Status: AmberFlupentixol tablets
Status: RedFluphenazine decanoate injection

Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion).

Status: AmberHaloperidol capsules

ESCA

Status: AmberHaloperidol decanoate injection

Specialist initiation only

Status: AmberHaloperidol injection
Status: AmberHaloperidol SF liquid

ESCA

Status: AmberHaloperidol tablets
Status: GreenHyoscine patch

Very high relative cost

Status: GreenHyoscine tablets

Specialist initiation only

Status: AmberLevomepromazine injection

Consultant initiation only

Status: AmberLevomepromazine tablets (Nozinan®)

Consultant initiation only, ESCA

Status: AmberLithium carbonate M/R tablet (Priadel)

Specialist initation only, ESCA

Status: AmberLithium citrate liquid priadel

Specialist initiation only, ESCA

Status: AmberOlanzapine orodispersible tablets

Specialist initiation only, ESCA

Status: AmberOlanzapine tablets

Specialist initiation only, ESCA

Status: RedPaliperidone (Byannli®)

6 monthly injection

Status: RedPaliperidone (Trevicta®)
  • Third line option
  • Patient has been stable mentally for at least 12 months and had a stable dose of paliperidone palmitate monthly injection and has not required a dosage adjustment in the last six months
  • 12 months using the monthly injections and no dose adjustment for the last six months before considering the three-monthly injection
  • APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion)
Status: RedPaliperidone (Xeplion®)

APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion) 

Status: RedPirenzipine

Unlicensed

Status: GreenProcyclidine SF syrup

Specialist initiation only

Status: GreenProcyclidine tablets

Specialist initiation only

Status: AmberQuetiapine tablets

Specialist initiation only, ESCA

Status: AmberQuetiapine XL tablets

Supported by ESCA. The GP should be given a rationale for prescribing rather than first line antipsychotics. Brand rationalisation - APC preferred brads Biquelle XL, Sondate XL, Zaluron XL

Status: RedRisperidone injection

APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion) 

Status: AmberRisperidone liquid

ESCA

Status: AmberRisperidone tablets

ESCA

Status: AmberSulpiride tablets

ESCA

Status: AmberTrifluoperazine SF solution

Specialist initiation only, ESCA

Status: AmberTrifluoperazine tablets

Specialist initiation only, ESCA

Status: AmberTrihexyphenidyl

Specialist initiation only

Status: AmberValproic acid as semisodium valproate tablets

Specialist initiation only

Status: RedZuclopenthixol decanoate injection

APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)  

Status: AmberZuclopenthixol tablets

Specialist initiation only, ESCA

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.

Building healthier lives
Back to top